BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GenPath Pharmaceuticals, Inc. 

300 Technology Square, 7th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-250-5950 Fax:


SEARCH JOBS


COMPANY MISSION
To discover and develop innovative cancer therapeutics.

COMPANY OVERVIEW
GenPath is focused on the discovery and development of drugs that target gene products critical for the maintenance and recurrence of established cancers.

GenPath utilizes a novel approach by applying recent breakthroughs from leading cancer research centers. Central to this approach is the use of inducible, spontaneous cancer models that more faithfully reproduce the human disease and make it possible for the first time to discover genes involved in tumor maintenance and recurrence. These same models will be used to assess the in-vivo effects of drug candidates and to identify disease or disease stage-specific biomarkers. The biomarkers will facilitate preclinical candidate selection and accelerate clinical development by improving patient selection and providing methods for early assessment of clinical efficacy.

With a powerful technology platform that begins with the right models and identifies the right genes, the right drugs, and right patients, and led by an accomplished team of managers, scientists, and investors, GenPath is making rapid progress in discovering and developing innovative cancer therapeutics.

TECHNOLOGY PLATFORM
The Right Genes
By applying GenPath's proprietary MaSS Screen technology to the inducible cancer models, genes essential for tumor maintenance and recurrence can be discovered. These genes have thus far escaped traditional research efforts despite their potential importance for cancer treatment.

Once identified, candidate cancer genes are rapidly evaluated in-vivo by examining the ability of RNAi knockdown of that gene to block tumor growth. GenPath's Therapeutic Window technology also provides unprecedented, early insight into the efficacy and safety of the cancer gene as a potential drug target.

The Right Drugs
By more faithfully reproducing the human disease, GenPath's proprietary models will identify drug candidates with a greater likelihood of success in clinical development. GenPath will also make use of advanced genomics and proteomics tools to compare the in-vivo molecular signature of each compound to that obtained with an RNAi knockdown of the new cancer gene. This will allow GenPath to select drug candidates that produce the desired therapeutic effect with maximum selectivity.

The Right Patients
GenPath's models will also be used to identify cancer stage-specific biomarkers. These biomarkers will aid in patient selection and provide surrogate markers for earlier assessments of efficacy, ultimately accelerating clinical development and enabling GenPath to deliver innovative new therapies to the patients who can benefit most from them.

MANAGEMENT TEAM
Tuan Ha-Ngoc
Chief Executive Officer
Steven Clark, PhD
Chief Scientific Officer
Elan Ezickson
Chief Business Officer
Peter Courossi
Chief Financial Officer
Jeno Gyuris, PhD
VP Molecular Technology
Murray Robinson, PhD
VP Oncology

FOUNDERS & KEY SCIENTIFIC CONTRIBUTORS
Lynda Chin, MD (Co-Founder)
Dana Farber Cancer Institute,
Harvard Medical School
Ronald DePinho, MD (Co-Founder)
Dana Farber Cancer Institute,
Harvard Medical School
Lewis Cantley, PhD
Harvard Medical School
Tyler Jacks, PhD
MIT Center for Cancer Research
Robert Horvitz, PhD
Professor of Biology, MIT
Richard Klausner, MD
Bill & Melinda Gates Foundation
National Cancer Institute
Raju Kucherlapati, PhD
Harvard-Partners Center for
Genetics and Genomics
David Livingston, MD
Dana Farber Cancer Institute,
Harvard Medical School
Edward Scolnick, MD
Merck Research Laboratories

Last Updated: 06-13-03


 Key Statistics


Email: hr@genpathpharma.com
Ownership: Private

Web Site: GenPath Pharmaceuticals, Inc.
Employees:
Symbol: 
 



Industry
Biotechnology

Segment
Drug Discovery





 Company News
BioReference Laboratories, Inc. (BRLI) to Launch Groundbreaking Solid Tumor Genotyping Test through its GenPath Pharmaceuticals, Inc. Oncology Laboratory 1/26/2012 6:56:36 AM    More...
GenPath Pharmaceuticals, Inc. Becomes AVEO Pharmaceuticals, Inc. 10/19/2005 5:12:52 PM    More...
GenPath Pharmaceuticals, Inc. And Merck & Co. (MRK) Enter Into Potential $100 Million Deal For The Discovery Of Novel Cancer Drugs 10/19/2005 5:10:47 PM    More...